BCL2 and Hyperglycemia: Bcl-2 assessment showed a remarkable decrease in the hyperglycemia (p < 0.001), hyperglycemia + SLN containing myricitrin 1 (p < 0.01) and 3 μM (p < 0.05) groups when compared to the control.